N/A
Manufactured by Pfizer Laboratories Div Pfizer Inc
37,114 FDA adverse event reports analyzed
Last updated: 2026-04-14
AXITINIB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Pfizer Laboratories Div Pfizer Inc. The most commonly reported adverse reactions for AXITINIB include DEATH, DIARRHOEA, FATIGUE, NEOPLASM PROGRESSION, HYPERTENSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AXITINIB.
Out of 18,985 classified reports for AXITINIB:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 37,114 FDA FAERS reports that mention AXITINIB. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, DIARRHOEA, FATIGUE, NEOPLASM PROGRESSION, HYPERTENSION, DISEASE PROGRESSION. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Pfizer Laboratories Div Pfizer Inc in connection with AXITINIB. Always verify the specific product and NDC with your pharmacist.